Skip to main content

A Constipation Drug Shows Promise in Protecting Kidneys

Published on June 22, 2026, 12:37 p.m.
A Constipation Drug Shows Promise in Protecting Kidneys

Topic: Health

Researchers found that a drug used to treat constipation may also slow down kidney damage. This could lead to new ways to treat chronic kidney disease.

Chronic kidney disease affects hundreds of millions of people worldwide and is one of the leading causes of kidney failure. As the disease progresses, many patients eventually need dialysis to survive.

Researchers at Tohoku University Graduate School of Medicine discovered that a drug used to treat constipation may help slow down kidney damage. The drug, lubiprostone, was given to patients with moderate chronic kidney disease in a clinical trial. The results showed that the drug slowed down the decline of kidney function compared to a placebo group.

The researchers found that lubiprostone increased the production of spermidine, a naturally occurring compound that helps keep mitochondria healthy. Mitochondria are often described as the power plants of cells because they generate the energy cells need to function properly. The researchers believe that improved mitochondrial function may help shield kidney tissue from further damage.

The study has drawn attention because lubiprostone is already an approved medication for chronic constipation, potentially making future clinical use faster than developing a completely new drug from scratch.

Why It Matters

This discovery could lead to new ways to treat chronic kidney disease, which affects many people in India. It also shows that the gut microbiome plays a crucial role in our overall health and well-being.

Key Facts

  • A clinical trial found that lubiprostone slowed down kidney damage in patients with moderate chronic kidney disease.
  • Lubiprostone increased the production of spermidine, which helps keep mitochondria healthy.
  • The study showed that improved mitochondrial function may help shield kidney tissue from further damage.
  • Lubiprostone is already an approved medication for chronic constipation, potentially making future clinical use faster than developing a completely new drug from scratch.
  • Chronic kidney disease affects hundreds of millions of people worldwide and is one of the leading causes of kidney failure.

Key Terms

Mitochondria
The power plants of cells that generate energy for cell function

Implications

This discovery could lead to new ways to treat chronic kidney disease, which affects many people in India. It also shows that the gut microbiome plays a crucial role in our overall health and well-being.


Source: https://www.sciencedaily.com/releases/2026/05/260508024740.htm

Journal Reference:

  1. Shun Watanabe, Masaaki Nakayama, Takashi Yokoo, Satoru Sanada, Yoshifumi Ubara, Atsushi Komatsuda, Katsuhiko Asanuma, Yusuke Suzuki, Tsuneo Konta, Junichiro J. Kazama, Takehiro Suzuki, Shinji Fukuda, Tomoyoshi Soga, Takuji Yamada, Sayaka Mizutani, Mitsuharu Matsumoto, Yuji Naito, Kensei Taguchi, Kei Fukami, Hitomi Kashiwagi, Koichi Kikuchi, Chitose Suzuki, Hidetaka Tokuno, Marina Urasato, Ryota Kujirai, Yotaro Matsumoto, Yasutoshi Akiyama, Yoshihisa Tomioka, Shun Itai, Yoshiyasu Tongu, Eikan Mishima, Chiharu Kawabe, Tomoko Kasahara, Yoshiaki Ogata, Takafumi Toyohara, Takeya Sato, Tetsuhiro Tanaka, Takaaki Abe. Lubiprostone in chronic kidney disease: Insights into mitochondrial function and polyamines from a randomized phase 2 clinical trial. Science Advances, 2025; 11 (35) DOI: 10.1126/sciadv.adw3934

Leave a Comment

Name
Email
Body
... ...

Get Exclusive Insights

with Every Issue

JoinShalyamNewsletter

Stay ahead in education, research, and innovation—straight to your inbox.